NexHealth raises $1.5M for appointment-booking app

By Heather Mack
01:25 pm

New York City-based NexHealth, maker of an app-based appointment-booking and patient communication platform, has raised $1.5 million in seed funding in a round led by iSeed Ventures.

The company, which launched in early 2015, works to increase access and flexibility for patients while increasing profits and reducing operating costs for providers, and the company already has partnerships with providers such as New York School of Medicine and National Dental.

Once a provider signs up with NexHealth, the platform integrates the provider’s schedule across every available digital channel. Whenever they get a new patient, they are asked to download the app to easily book, cancel or check in for appointments, plus ask questions to the office and get responses and reminders via text or email. 

“Today marks a major step forward for our company,” NexHealth CEO and cofounder Alamin Uddin said in a statement. “Leveraging our partnerships with major provider networks like National Dental and academic health centers like New York School of Medicine, we now have the foundation in place to give patients better access to their doctors across all digital channels, while making it easier for providers to increase income."

Uddin was prompted to create NexHealth while working as an administrator at a primary care facility in Brooklyn, where when he saw challenges arise in patient care and compliance from a lack of patient access. Calling the NexHealth solution a model of “patient access anywhere and anytime,” Uddin said the company will use the funds to grow its network of doctors, patients and product offerings.

On the provider’s side, they can save time and money by quickly filling canceled appointments and automating daily staff tasks like wait-lists and recalls.

“Partnering with NexHealth, we aim to reduce our high no-show that’s hurting us financially, better utilize physician slots, as well as give our patients better access to our physicians,” New York School of Medicine’s Dr. Jerry Balentine said in a statement.